Trial Profile
A Randomised, Double-blind, Placebo-controlled, Multicentre Trial Exploring the Efficacy and Safety of Intra-nasal Administration of FE 202767 in Increasing Milk Production in Maternal Subjects With Preterm Delivery and Inadequate Milk Production
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Merotocin (Primary)
- Indications Lactation failure
- Focus Therapeutic Use
- Acronyms MERMAID
- Sponsors Ferring Pharmaceuticals
- 13 Jan 2023 Status changed from recruiting to discontinued.
- 28 Mar 2022 Planned End Date changed from 1 Sep 2023 to 1 Oct 2023.
- 28 Mar 2022 Planned primary completion date changed from 1 Sep 2023 to 1 Oct 2023.